Agilent Technologies Inc. has unveiled its new Biopharma CDx Services Lab (BCSL) in Carpinteria, California, marking a significant stride in the field of precision medicine. This state-of-the-art facility is poised to revolutionize the drug development process by streamlining the journey from early
Autoimmune diseases, affecting millions of people worldwide, present a unique challenge where the body's immune system mistakenly attacks its tissues. Existing treatments primarily rely on immunosuppressants, which often come with severe side effects and don’t always offer a cure. Enter Candid
In a significant advancement for non-small cell lung cancer (NSCLC) treatment, Akeso and Summit Therapeutics have revealed astounding results from their phase 3 HARMONi-2 trial. Ivonescimab, a PD-1/VEGF bispecific antibody, has demonstrated remarkable efficacy against Merck’s Keytruda, positioning i
BlueRock Therapeutics, a cell therapy company under Bayer, has recently announced FDA clearance for its Investigational New Drug (IND) application for OpCT-001. This investigational induced pluripotent stem cell (iPSC)-derived therapy aims to treat primary photoreceptor diseases, which are a
Rentschler Biopharma has recently unveiled an innovative lentiviral vector (LVV) manufacturing toolbox at its advanced therapies site in Stevenage, United Kingdom, significantly enhancing its service offerings in the gene therapy sector. This strategic expansion complements their established
In the evolving landscape of cancer treatment, the advent of immunotherapies Keytruda and Opdivo has marked a groundbreaking shift. Over the last decade, these drugs, known as PD1 inhibitors, have revolutionized oncology, offering new hope and significantly altering patient outcomes. Their story is
